Date: November 05, 2026

To, **National Stock Exchange of India Limited,** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Scrip Symbol: **PARASHLTH**	To, **BSE Limited,** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 BSE Scrip Code: **545005**

Subject: Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, as amended, please find attached the Press Release on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.

This Press Release will also be hosted on the Company's website at https://www.parashospitals.com/investors.

We request you to kindly take the same on record.

Thanking you.

For **Paras Healthcare Limited**

Rahul Kumar
Digitally signed by Rahul Kumar
Date: 2026.11.05 19:30:15 +05'30'

Rahul Kumar
Company Secretary and Compliance Officer
ICSI Membership No.: A20928

Press Release

Paras Health reports robust revenue growth of 23% in Q2 YoY to Rs. 511 cr; EBITDA up 43% YoY; PAT up 3.3x YoY

Gurugram, November 5, 2026: Paras Healthcare Limited ("Paras Health"), a clinical specialty led hospital platform and one of the largest healthcare providers in North India, Bihar and Jharkhand, announced today its first unaudited consolidated financial results for the quarter and six months period ended September 30, 2026, since listing on the stock exchanges on October 28, 2026.

Financial Snapshot for the Quarter and six months period ended September 30, 2026 (Consolidated)

Particulars (Rs. crore)	Q2 FY27	Q2 FY26	Change YoY	Q1 FY27	Change QoQ
Revenue from Operations	**510.9**	416.1	**+22.8%**	470.3	**+8.6%**
EBITDA	**126.6**	88.8	**+42.5%**	113.5	**+11.6%**
EBITDA Margin	*24.5%*	*21.0%*	*+350 bps*	*23.7%*	*+80 bps*
Profit after Tax (PAT)	**40.4**	12.4	**3.3x**	49.7	
PAT Margin	*7.8%*	*2.9%*	*+490 bps*	*10.4%*	

Particulars (Rs. crore)	H1 FY27	H1 FY26	Change YoY
Revenue from Operations	**981.2**	784.5	**+25.1%**
EBITDA	**240.1**	155.2	**+54.7%**
EBITDA Margin	*24.1%*	*19.5%*	*+460 bps*
Profit after Tax (PAT)	**90.0**	11.4	**8.7x**
PAT Margin	*9.0%*	*1.4%*	*+760 bps*

Key Highlights for the Quarter and Half year

- Q2 Revenue from operations was **Rs. 510.9 crore, up 22.8% YoY** and 8.6% QoQ
- EBITDA was **Rs. 126.6 crore, up 42.5% YoY**; EBITDA margin expanded by **350 bps YoY to 24.5%**
- PAT was **Rs. 40.3 crore, 3.6x YoY**, with PAT margin improving to 7.8% from 2.7%
- New hospitals at Srinagar and Kanpur more than doubled revenue in Q2 YoY to Rs. 84.4 crore, with **EBITDA at 18.7% margin**
- **H1 FY27 revenue of Rs. 981.2 crore**, up 25.1% YoY; **H1 PAT of Rs. 90.0 crore, 7.9x YoY**
- *For H1FY26, occupied bed days have grown by **23.9%** to 201K from 162K*
- *Bed occupancy rose to **73.0% in H1 FY27** from 59.0% in H1 FY26; **ARPOB is at Rs. 48.9K***

Commenting on the performance, Dr. Dharminder Kumar Nagar, Managing Director, Paras Healthcare Limited, said, *"This quarter marks an important milestone for Paras Health as we report our first results as a listed company. We are pleased to deliver a robust performance, with the quarter revenue growing 22.8% YoY to Rs. 510.9 crore and PAT rising 3.6 times. Revenue for H1 FY27 at Rs 981 cr grew 25% YoY. Our newer hospitals at Srinagar and Kanpur have ramped up rapidly and turned strongly EBITDA positive, while our mature hospitals continue to deliver industry leading margins.*

Out of the IPO proceeds of Rs 500 crore, we deployed Rs 375 crore towards part repayment of our borrowings making our balance sheet significantly stronger. We will continue to deepen our specialty programmes including oncology, cardiac, neuro and renal sciences, invest in advanced clinical technology and expand our presence in the under served markets of North India."

About Paras Healthcare Limited

Paras Healthcare Limited (Paras Health) is a clinical specialty-led hospital platform providing tertiary and quaternary healthcare services through a network of eight hospitals with an aggregate bed capacity of 2,211 beds, including 559 ICU beds, as of September 30, 2026. Operating under the "Paras Health" brand, it has hospitals in Gurugram and Panchkula (Haryana), Patna and Darbhanga (Bihar), Kanpur (Uttar Pradesh), Udaipur (Rajasthan), Ranchi (Jharkhand) and Srinagar (Jammu and Kashmir). It has 2 more hospitals coming up in Gurugram Golf Course extension (300 beds) and Ludhiana (500 beds) by 2028. CONGOR specialties (cardiac, oncology, neuro, gastro, orthopaedics and renal sciences) accounted for 73.5% of revenue in H1 FY27.

Disclaimer

No representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The information contained is current only as of its date. Certain statements may be "forward-looking statements", including those relating to the Company's business plans and strategy, future financial condition and growth prospects, and its industry, competitive and regulatory environment. Actual results may differ materially due to a number of factors, including changes in the Company's business, its competitive environment, and political, economic, legal and social conditions in India.

For more information:

Mr. Dilip Bidani / Mr. Sidharth Aggarwal
Dilip.Bidani@parashealth.com/ Sidharth.Aggarwal@parashealth.com